Abstract |
The ability of 5-(3-tert-butylamino-2-hydroxy-propoxy)-3, 4-dihydro-2(1H)-quinolinone hydrochloride (carteolol hydrochloride, Endak, Endak mite) to lower the blood pressure was tested in an open clinical study on 66 patients with I-III degree essential hypertension. The results for 49 of the 66 patients were interpretable after 4 weeks, and for 39 of them after 12 weeks. Even with a single dose of 5 mg/day 33 of the patients had normalized blood pressures after 4 weeks (systolic less than 160, diastolic less than 95 mmHg); in a further 6 patients 10 mg led to normal blood pressure. For 10 patients, 4 weeks on 10 mg did not lead to an adequate response. After 12 weeks, of the 39 cases that could be checked, 19 were normalized on 5 mg, 2 on 10 mg and another 4 on 15 mg. Even 15 mg was insufficient to reduce the blood pressure of 14 of the patients adequately. Carteolol, at doses of 5-15 mg/day, caused a therapeutically acceptable lowering of the blood pressure in 60-80% of cases of essential hypertension of all 3 degrees of severity. Only 5 of the patients suffered from side-effects, none of which caused the treatment to be abandoned. A bradycardia was never observed during up to 12 weeks of continuous treatment. Tachycardias reverted to sinus rhythms of normal frequency. Blood pressure measurement by the patients themselves proved successful.
|
Authors | R D Beythien |
Journal | Arzneimittel-Forschung
(Arzneimittelforschung)
Vol. 33
Issue 2a
Pg. 330-3
( 1983)
ISSN: 0004-4172 [Print] Germany |
Vernacular Title | Die hypotensive Wirkung von Carteolol bei Patienten mit essentieller Hypertonie. |
PMID | 6682325
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Blood Pressure
(drug effects)
- Carteolol
(adverse effects, therapeutic use)
- Female
- Heart Rate
(drug effects)
- Humans
- Hypertension
(drug therapy)
- Male
- Middle Aged
- Propanolamines
(therapeutic use)
|